November 26, 2020
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the composition of the Nomination Committee for the Annual General Meeting 2021.
Pursuant to the instruction and charter for the Nomination Committee adopted by the general meeting, the Nomination Committee shall be comprised of three members, which shall be the Chairman of the Board of Directors and two members appointed by the two largest shareholders as of last September. On September 30, 2020, the two largest shareholders, which desired to appoint a representative to the Nomination Committee, were Jørgen Drejer and New Leaf Venture Partners. Each such shareholder has appointed a representative, as shown below, who together with the Chairman of the Board of Directors will form Saniona AB’s Nomination Committee.
The Nomination Committee’s members are:
The Nomination Committee shall prepare and submit proposals to the Annual General Meeting 2021 regarding:
The instruction and charter for the Nomination Committee in Saniona AB can be found in the Corporate Governance section at the company’s website, www.saniona.com.
Saniona AB’s Annual General Meeting will be held on Wednesday, May 26, 2021, in Malmö. The Nomination Committee’s proposals will be presented in the notice to the Annual General Meeting and on the company’s web site.
Shareholders who would like to submit proposals to the Nomination Committee can do so via e-mail to email@example.com marked “Recommendation to the Nomination Committee” or by ordinary mail to the address:
Recommendation to the Nomination Committee
Smedeland 26B, DK-2600
To ensure that the proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but not later than February 25, 2021.
For more information, please contact
Trista Morrison, Chief Communications Officer. Office + 1 (781) 810-9227. Email: firstname.lastname@example.org
The information was submitted for publication, through the agency of the contact person set out above, at 16.00 CET on November 26, 2020.
Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical development. Saniona intends to develop and commercialize treatments for rare disease indications such as hypothalamic obesity and Prader-Willi syndrome on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona also has out-licensing agreements with several companies. Saniona is based in Copenhagen, Denmark, and in Boston, Mass., U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.